Reboxetine Versus Fluvoxamine in the Treatment of Motor Vehicle Accident-related Posttraumatic Stress Disorder
- 1 April 2006
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Psychopharmacology
- Vol. 26 (2), 152-156
- https://doi.org/10.1097/01.jcp.0000203195.65710.f0
Abstract
Motor vehicle accidents (MVAs) are a leading cause of posttraumatic stress disorder (PTSD) in the general population. Alterations in norepinephrine and serotonin systems have been proposed as mechanisms involved in the pathophysiology of the condition, with treatment directed at these neurotransmitter systems. Reboxetine, a selective norepinephrine reuptake inhibitor, exhibits high affinity and selectivity for the human norepinephrine transporter. Inasmuch as PTSD may be associated with dysregulation of noradrenergic activity, the present double-blind randomized clinical trial intended to evaluate reboxetine's efficacy in the management of MVA-related PTSD and to compare its efficacy with a medication commonly used in PTSD, the selective serotonin reuptake inhibitor fluvoxamine.Forty patients with MVA-related PTSD attending a local community mental health outpatient clinic were randomized to receive a fixed dose of either reboxetine (8 mg/d) or fluvoxamine (150 mg/d) in a double-blind fashion for a period of 8 weeks.At baseline and at study end point, the 2 subgroups demonstrated no statistical differences in scores on PTSD, depression, and anxiety rating scales. Both medications led to significant improvements in all clinical scales measured. Nine patients receiving reboxetine and 3 receiving fluvoxamine withdrew from the study because of side effects.Study observations indicate comparable efficacy of reboxetine and fluvoxamine in the management of MVA-related PTSD despite reboxetine's selective noradrenergic activity. Reboxetine appears to be at least as effective as fluvoxamine and may offer an alternative management option in this often difficult-to-treat and disabling condition. A lower and flexible reboxetine dosing schedule will be recommended for future research to improve its tolerability in PTSD patients.Keywords
This publication has 33 references indexed in Scilit:
- Review of sertraline in post-traumatic stress disorderExpert Opinion on Pharmacotherapy, 2002
- Paroxetine in the Treatment of Chronic Posttraumatic Stress DisorderThe Journal of Clinical Psychiatry, 2001
- A role for norepinephrine in stress-induced cognitive deficits: α-1-adrenoceptor mediation in the prefrontal cortexBiological Psychiatry, 1999
- Fluoxetine in post-traumatic stress disorderThe British Journal of Psychiatry, 1999
- Psychiatric morbidity following motor vehicle accidents: A review of methodological issuesComprehensive Psychiatry, 1998
- Psychiatric consequences of road traffic accidents.BMJ, 1993
- Abnormal Noradrenergic Function in Posttraumatic Stress DisorderArchives of General Psychiatry, 1993
- Treatment of Posttraumatic Stress Disorder With Amitriptyline and PlaceboArchives of General Psychiatry, 1990
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959